Flow cytometric analysis of Daudi (Human Burkitt's lymphoma lymphoblast, Left) / U-937 (Human histiocytic lymphoma monocyte, Right) labelling CD257 antibody at 1/400 dilution (0.5 μg) / (Red) compared with a Mouse IgG2a, κ (Black) isotype control and an unlabelled control (cells without incubation with primary antibody and secondary antibody) (Blue). Goat Anti - Mouse IgG Alexa Fluor® 647 was used as the secondary antibody. Negative control: Daudi
Product Details
Product Details
Product Specification
| Host | Mouse |
| Antigen | CD257 |
| Synonyms | Tumor necrosis factor ligand superfamily member 13B; B lymphocyte stimulator (BLyS); B-cell-activating factor; BAFF; Dendritic cell-derived TNF-like molecule; TNF- and APOL-related leukocyte expressed ligand 1 (TALL-1); BLYS; TALL1; TNFSF20; ZTNF4; TNFSF13B |
| Location | Cell membrane |
| Accession | Q9Y275 |
| Clone Number | S-3021 |
| Antibody Type | Mouse mAb |
| Isotype | IgG2a,k |
| Application | FCM |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4 |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1:400 | Hu |
Background
CD257, encoded by TNFSF13B and also known as BLyS or BAFF, is a 285-aa type-II transmembrane glycoprotein of the TNF ligand superfamily produced by monocytes, dendritic cells, macrophages and activated T cells that can be cleaved to a soluble homotrimeric cytokine which, via engagement of three receptors—BAFF-R, TACI and BCMA—delivers survival and maturation signals to B cells, orchestrates T-cell co-stimulation, and drives class-switching and antibody production through NF-κB and PI3K/AKT pathways, while excess CD257 triggers B-cell hyperplasia and autoantibody formation, linking its overexpression to systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis and multiple myeloma, and making CD257 antagonism (e.g., belimumab) a validated therapeutic strategy.
Picture
Picture
FC
